Skip to main content
SpringerLink
Log in

Bicalutamide

A Viewpoint by Richard K. Lo

  • Adis Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000 Apr 29; 355(9214): 1491–8

    Article  Google Scholar 

  2. See W, Wirth M, McLeod DG, et al. Bicalutamide (Casodex) as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429–35

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Hong Kong, Hong Kong

    Richard K. Lo

Authors
  1. Richard K. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lo, R.K. Bicalutamide. Drugs 62, 2480 (2002). https://doi.org/10.2165/00003495-200262170-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262170-00007

Search

Navigation